JP2021510736A5 - - Google Patents

Info

Publication number
JP2021510736A5
JP2021510736A5 JP2020559030A JP2020559030A JP2021510736A5 JP 2021510736 A5 JP2021510736 A5 JP 2021510736A5 JP 2020559030 A JP2020559030 A JP 2020559030A JP 2020559030 A JP2020559030 A JP 2020559030A JP 2021510736 A5 JP2021510736 A5 JP 2021510736A5
Authority
JP
Japan
Prior art keywords
sequence number
amino acid
acid sequence
seq
antibody molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559030A
Other languages
English (en)
Japanese (ja)
Other versions
JP7511479B2 (ja
JP2021510736A (ja
Filing date
Publication date
Priority claimed from GBGB1800649.4A external-priority patent/GB201800649D0/en
Application filed filed Critical
Publication of JP2021510736A publication Critical patent/JP2021510736A/ja
Publication of JP2021510736A5 publication Critical patent/JP2021510736A5/ja
Priority to JP2023202413A priority Critical patent/JP2024037765A/ja
Application granted granted Critical
Publication of JP7511479B2 publication Critical patent/JP7511479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559030A 2018-01-16 2019-01-16 Cd70組合せ療法 Active JP7511479B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023202413A JP2024037765A (ja) 2018-01-16 2023-11-30 Cd70組合せ療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800649.4A GB201800649D0 (en) 2018-01-16 2018-01-16 CD70 Combination Therapy
GB1800649.4 2018-01-16
PCT/EP2019/051058 WO2019141732A1 (en) 2018-01-16 2019-01-16 Cd70 combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023202413A Division JP2024037765A (ja) 2018-01-16 2023-11-30 Cd70組合せ療法

Publications (3)

Publication Number Publication Date
JP2021510736A JP2021510736A (ja) 2021-04-30
JP2021510736A5 true JP2021510736A5 (https=) 2022-02-09
JP7511479B2 JP7511479B2 (ja) 2024-07-05

Family

ID=61256176

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020559030A Active JP7511479B2 (ja) 2018-01-16 2019-01-16 Cd70組合せ療法
JP2023202413A Pending JP2024037765A (ja) 2018-01-16 2023-11-30 Cd70組合せ療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023202413A Pending JP2024037765A (ja) 2018-01-16 2023-11-30 Cd70組合せ療法

Country Status (22)

Country Link
US (2) US11530271B2 (https=)
EP (2) EP4275702A3 (https=)
JP (2) JP7511479B2 (https=)
KR (1) KR102790232B1 (https=)
CN (1) CN111836830B (https=)
AU (1) AU2019209503B2 (https=)
BR (1) BR112020014321A2 (https=)
CA (1) CA3086448A1 (https=)
DK (1) DK3740504T5 (https=)
EA (1) EA202091714A1 (https=)
ES (1) ES2956258T3 (https=)
FI (1) FI3740504T3 (https=)
GB (1) GB201800649D0 (https=)
HU (1) HUE063783T2 (https=)
IL (1) IL276103A (https=)
LT (1) LT3740504T (https=)
MX (1) MX2020007606A (https=)
PL (1) PL3740504T3 (https=)
PT (1) PT3740504T (https=)
SG (1) SG11202006007YA (https=)
WO (1) WO2019141732A1 (https=)
ZA (1) ZA202003986B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
BR112021005585A2 (pt) 2018-09-27 2021-06-29 Celgene Corporation proteínas de ligação a sirpa e métodos de uso das mesmas
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
WO2021053490A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis
BR112022012310A2 (pt) * 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
WO2021226289A2 (en) * 2020-05-05 2021-11-11 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
WO2022087416A1 (en) * 2020-10-22 2022-04-28 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
CN114765061B (zh) * 2021-01-15 2024-12-27 深圳哲源生物科技有限责任公司 Pd-1/pd-l1抑制剂的不良预后的数据处理系统及方法
CN113150140B (zh) * 2021-01-25 2022-11-04 山西农业大学 一种sox6二价纳米抗体及其应用
TW202317190A (zh) * 2021-06-29 2023-05-01 美商思進公司 以非岩藻糖基化抗cd70抗體及cd47拮抗劑之組合治療癌症之方法
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
DE19747418C1 (de) 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6500633B1 (en) 2000-04-26 2002-12-31 Atairgin Technologies, Inc. Method of detecting carcinomas
US20030148321A1 (en) 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
EP1470247A2 (en) 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
ES2394018T3 (es) 2001-11-27 2013-01-15 Ucb Pharma S.A. Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales
US7261892B2 (en) 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8039218B2 (en) 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
JP5356648B2 (ja) 2003-02-20 2013-12-04 シアトル ジェネティックス, インコーポレイテッド 抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
JP2007525438A (ja) 2003-03-24 2007-09-06 ザイモジェネティクス, インコーポレイテッド 抗il−22ra抗体および結合パートナー、ならびに炎症における使用法
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006044643A2 (en) 2004-10-15 2006-04-27 Seattle Genetics, Inc. Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
AU2005299809B2 (en) 2004-10-22 2010-12-02 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP1872124A4 (en) 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSIS MARKET FOR BREAST CANCER TREATMENT AND PROGRESSION AND METHOD OF USE THEREOF
JP5122441B2 (ja) 2005-04-19 2013-01-16 シアトル ジェネティックス, インコーポレイテッド ヒト化抗cd70結合剤およびその使用
WO2007011856A2 (en) 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
KR100807069B1 (ko) 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
US20100267626A1 (en) 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010014948A1 (en) 2008-08-01 2010-02-04 The University Of Utah Research Foundation Methods of treatment using wnt inhibitors
WO2010019921A2 (en) 2008-08-15 2010-02-18 The Regents Of The University Of California Biomarkers for diagnosis and treatment of chronic lymphocytic leukemia
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
JP5748653B2 (ja) 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗tim−3抗体を用いた血液腫瘍治療法
CN105037355B (zh) 2009-08-10 2017-06-06 萨穆梅德有限公司 Wnt信号传导途径的吲唑抑制剂及其治疗用途
US20120178111A1 (en) 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
UA105405C2 (ru) 2009-11-19 2014-05-12 Мерк Сероно С.А. Гуманизированное антитело против человеческого il-22ra
KR101773216B1 (ko) 2009-12-29 2017-08-31 교와 핫꼬 기린 가부시키가이샤 항 cd27 항체
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
US9403906B2 (en) 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
MX353958B (es) 2011-09-22 2018-02-07 Amgen Inc Proteinas de union al antigeno cd27l.
WO2013093508A2 (en) 2011-12-22 2013-06-27 Oslo University Hospital Hf Wnt pathway inhibitors
NZ629697A (en) 2012-03-15 2017-01-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
KR20140145148A (ko) 2012-03-21 2014-12-22 에리테끄 파르마 급성 골수성 백혈병 치료를 위한 약제
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
EP2861590B1 (en) 2012-06-15 2017-10-25 Curegenix Inc. Compound as wnt signaling inhibitor, composition, and use thereof
EP2977386A1 (en) 2012-08-31 2016-01-27 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
WO2014100772A1 (en) 2012-12-21 2014-06-26 Cellerant Therapeutics, Inc. Antibodies that bind membrane-bound il1rap
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
CN106456749B (zh) * 2014-03-11 2021-03-30 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
TWI717375B (zh) * 2015-07-31 2021-02-01 德商安美基研究(慕尼黑)公司 Cd70及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
US20180244792A1 (en) * 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
PE20181326A1 (es) 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
US20220136068A1 (en) 2019-03-06 2022-05-05 The Regents Of The University Of Colorado, A Body Corporate Methods of detecting and treating venetoclax-resistant acute myeloid leukemia
KR20230061421A (ko) 2020-08-29 2023-05-08 아르제넥스 비브이 Bcl-2 억제제에 대한 감소된 민감도를 가진 환자를 치료하는 방법
EP4225949A1 (en) 2020-10-06 2023-08-16 The Regents of the University of Colorado, a body corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia

Similar Documents

Publication Publication Date Title
JP2021510736A5 (https=)
CN110914306B (zh) 检查点抑制物双特异性抗体
CN105452294B (zh) 癌的治疗和/或预防用药物组合物
CN104114583B (zh) 癌的治疗和/或预防用药物组合物
CN105636986B (zh) 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
JP2021527431A5 (https=)
JP2019536430A5 (https=)
JP2019536470A5 (https=)
JP2021524256A5 (https=)
JP2021526509A5 (https=)
JP2022515077A5 (https=)
JP2020501531A5 (https=)
JP2019503361A (ja) がんを治療するための抗pd−1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
JP2018534933A5 (https=)
JP2017529838A5 (https=)
CN116396386A (zh) Cd3抗体及其药物用途
JP2017535257A5 (https=)
JP2013502913A5 (https=)
JP2022533538A5 (https=)
JP2020522281A5 (https=)
JP2020522280A5 (https=)
JP2025038088A5 (https=)
JP2020515577A5 (https=)
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2023504733A (ja) 抗clec-1a抗体及びその抗原結合性断片